Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UBS Warburg Global Lifesciences Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

Angiotech Pharmaceuticals: Canadian firm will not develop another compound for use in drug-eluting stents beyond paclitaxel, but intends to replicate the stent model using the drug for other devices including peripheral stents and surgical adhesives, the company affirms Oct. 10. Angiotech claims that the physician's choice of paclitaxel versus siroliumus is more important to the company than whether Guidant and Boston Scientific are on the market with a paclitaxel stent. "The stent is secondary, and I don't think it is as important as people play it out to be," CEO William Hunter comments. The exec also suggests that equivalency trials for drug-eluting stents could be much harder to conduct in the future, claiming that it could take between 5,000 and 10,000 patients to prove a statistical difference between 4% and 5% restenosis rates. Hunter expects a federal ruling on Guidant's proposed consolidation with Cook Group for access to paclitaxel "in the next month...but I don't think it will be that clean"...

You may also be interested in...

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts